Solanezumab

Solanezumab is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease (AD), preclinical AD, and dominantly inherited AD.

Solanezumab research

Phase 1 and 2 studies showed a good tolerance and safety profile for Solanezumab in healthy volunteers and in participants with mild to moderate AD.

However, a Phase 3 study in people with AD with mild dementia called EXPEDITION 3 (NCT01900665) did not meet the primary objective, which was the measure of the change from baseline in AD assessment cognitive scale, and has been terminated.

Other Phase 3 studies to assess the continued efficacy and safety in people with AD (NCT01127633) and to investigate the safety and efficacy of solanezumab in people with prodromal AD (NCT02760602) have also been terminated because solanezumab did not meet the primary endpoint like in the EXPEDITION 3 study and there was not enough scientific evidence that solanezumab would likely demonstrate a meaningful benefit to people with prodromal AD.

Although the results of these studies were disappointing, solanezumab continues to be tested in people with a genetic mutation who might be at risk for developing AD (NCT01760005). The estimated study completion date is December 2019.

Another Phase 3 study (NCT02008357) is currently recruiting participants who do not have memory loss but have evidence of amyloid beta buildup in the brain. This study aims to assess whether solanezumab can slow the progression of memory problems associated with brain amyloids. The estimated study completion date is October 2020.

Note: Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Disclaimer:

Alzheimer's News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more